Nurix Therapeutics Inc
$ 16.83
2.94%
03 Dec - close price
- Market Cap 1,706,044,000 USD
- Current Price $ 16.83
- High / Low $ 17.46 / 16.25
- Stock P/E N/A
- Book Value 4.84
- EPS -2.97
- Next Earning Report 2026-02-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -0.65 %
- 52 Week High 22.95
- 52 Week Low 8.18
About
Nurix Therapeutics, Inc. is a San Francisco-based biopharmaceutical company dedicated to revolutionizing cancer and immune disorder treatments through the development of innovative small molecule therapies. Leveraging its proprietary drug discovery platform, the company focuses on targeted protein degradation, a method that opens new avenues for improving patient outcomes in oncology and immunology. With a robust pipeline of candidates and a commitment to advancing next-generation therapeutics, Nurix presents a compelling investment opportunity for institutional investors seeking to engage in transformative health solutions.
Analyst Target Price
$27.18
Quarterly Earnings
| Aug 2025 | May 2025 | Feb 2025 | Nov 2024 | Aug 2024 | May 2024 | Feb 2024 | Nov 2023 | Aug 2023 | May 2023 | Feb 2023 | Nov 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-09 | 2025-07-09 | 2025-04-08 | 2025-02-13 | 2024-10-11 | 2024-07-11 | 2024-04-10 | 2024-02-15 | 2023-10-12 | 2023-07-13 | 2023-04-13 | 2023-02-09 |
| Reported EPS | -1.03 | -0.52 | -0.67 | -0.75 | -0.67 | -0.71 | -0.76 | -0.77 | -0.68 | -0.45 | -0.75 | -0.87 |
| Estimated EPS | -0.8296 | -0.714 | -0.7614 | -0.6689 | -0.71 | -0.63 | -0.8 | -0.57 | -0.76 | -0.56 | -0.87 | -0.79 |
| Surprise | -0.2004 | 0.194 | 0.0914 | -0.0811 | 0.04 | -0.08 | 0.04 | -0.2 | 0.08 | 0.11 | 0.12 | -0.08 |
| Surprise Percentage | -24.1562% | 27.1709% | 12.0042% | -12.1244% | 5.6338% | -12.6984% | 5% | -35.0877% | 10.5263% | 19.6429% | 13.7931% | -10.1266% |
Next Quarterly Earnings
| Nov 2025 | |
|---|---|
| Reported Date | 2026-02-18 |
| Fiscal Date Ending | 2025-11-30 |
| Estimated EPS | -0.8777 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NRIX
2025-10-18 07:10:00
Nurix Therapeutics announced promising Phase 1a clinical data for NX-1607, a first-in-class oral CBL-B inhibitor, showing anti-tumor activity and immune activation in 82 heavily pretreated patients with advanced solid tumors. The study revealed tumor shrinkage, long-term stable disease, and a confirmed partial response in micro-satellite stable colorectal cancer, a type typically unresponsive to immunotherapy. NX-1607 was well-tolerated, with a safety profile similar to other immuno-oncology agents, supporting further clinical development and expansion cohorts.
2025-10-18 07:00:00
Nurix Therapeutics presented new clinical data for its oral CBL-B inhibitor, NX-1607, at ESMO 2025, demonstrating single-agent activity across various solid tumor types. The data showed on-target peripheral immune activation, reductions in tumor biomarkers, long-term stable disease, and a confirmed partial response in heavily pretreated patients, including those with MSS colorectal cancer and metastatic prostate cancer, supporting its continued development as a novel immune checkpoint inhibitor.
2025-10-18 07:00:00
Nurix Therapeutics reported positive Phase 1a clinical data for its oral CBL-B inhibitor, NX-1607, at ESMO 2025, demonstrating single-agent activity across multiple tumor types. The study in 82 patients showed a 49.3% disease control rate and a confirmed partial response in a patient with MSS colorectal cancer, alongside dose-dependent immune activation and tumor biomarker reductions. These results support advancing NX-1607 into expansion cohorts as monotherapy or in combination for advanced solid tumors.
2025-10-16 11:58:27
HC Wainwright has lowered its FY2025 earnings per share estimate for Nurix Therapeutics (NASDAQ:NRIX) to ($3.18) from ($2.76), though maintaining a "Buy" rating and a $33.00 price target. This revision follows Nurix Therapeutics reporting a third-quarter EPS of ($1.03) and revenue of $7.89 million, both falling short of analysts' expectations. The article also notes recent insider stock sales and changes in holdings by hedge funds.
2025-10-15 17:41:27
Morgan Stanley has lowered its price target for Nurix Therapeutics (NASDAQ:NRIX) to $15.00 from $16.00. This research note follows several other analyst reports with varying price targets and ratings, including "strong-buy" and "overweight" recommendations, with a consensus target price of $27.79. The article also details recent insider transactions and institutional investment activity in Nurix Therapeutics.
2025-10-14 12:06:59
HC Wainwright & Co. has maintained its Buy rating for Nurix Therapeutics (NRIX) but lowered the price target from $34 to $33. This adjustment follows a trend of downward revisions from other analysts, indicating cautious market sentiment. Despite the lowered price target, the average analyst forecast still suggests a significant upside from the current stock price.
